Global Alogliptin Market Size By Type (6.25 Mg Tablet, 25 Mg Tablet), By Application (Diabetes, Hypercholesterolemia), By Region, And Segment Forecasts, 2023 to 2032

The Global Alogliptin Market was valued at USD 675 million in 2023 and is projected to reach USD 1.05 billion by 2031, growing at a CAGR of 5.7% during the forecast period from 2023 to 2031. Alogliptin, a DPP-4 inhibitor used in the management of type 2 diabetes, is gaining prominence due to the escalating global prevalence of diabetes, favorable clinical efficacy with fewer side effects, and increasing adoption in emerging markets. The growing geriatric population, rising awareness about diabetic therapies, and ongoing clinical advancements in combination therapies are expected to further propel market expansion.

Drivers:

1. Rising Global Prevalence of Type 2 Diabetes:

The global diabetes burden continues to climb, particularly in middle- and low-income countries. Alogliptin offers effective glycemic control with fewer hypoglycemic events, making it a preferred choice in chronic diabetes management.

2. Favorable Safety Profile and Tolerability:

Compared to other antidiabetic drugs, alogliptin exhibits a lower risk of cardiovascular events and minimal drug-drug interactions, promoting its use among elderly and comorbid patients.

3. Increasing Preference for Oral Antidiabetic Drugs:

Oral administration offers convenience over injectable alternatives, increasing patient compliance, which, in turn, supports the growth of DPP-4 inhibitors like alogliptin.

Restraints:

1. Patent Expiry and Generic Competition:

The expiration of key patents and the influx of generic versions is reducing market share for branded alogliptin formulations, impacting overall revenue growth.

2. Availability of Substitutes:

Alogliptin faces stiff competition from newer antidiabetic agents such as SGLT2 inhibitors and GLP-1 receptor agonists that offer superior glycemic control and cardiovascular benefits.

Opportunity:

1. Expansion in Emerging Markets:

Rising healthcare access and increased diagnosis rates in regions such as Asia-Pacific and Latin America are presenting untapped opportunities for alogliptin adoption.

2. Growth of Fixed-Dose Combinations (FDCs):

The development of alogliptin-based combination therapies (e.g., with metformin) is gaining regulatory approvals and boosting usage, especially in polytherapy management for diabetic patients.

Market by System Type Insights:

Based on drug formulation, oral tablets represented the largest segment in 2023. These are preferred for their ease of administration, dosage flexibility, and stability. The fixed-dose combination (FDC) segment, including alogliptin with metformin, is poised to grow rapidly due to enhanced therapeutic efficacy and simplified treatment regimens.

Market by End-use Insights:

The hospital pharmacy segment dominated the market in 2023, owing to the rising number of inpatient diabetes cases and strong presence of branded prescriptions in institutional settings. However, retail pharmacies are expected to exhibit substantial growth due to increasing outpatient treatment and accessibility of generics.

Market by Regional Insights:

North America held the largest market share in 2023, driven by advanced healthcare infrastructure, high diabetes prevalence, and early adoption of branded antidiabetic drugs. Asia-Pacific, especially India and China, is forecasted to experience the fastest growth rate, supported by rising awareness, urbanization, and expanding pharmaceutical markets.

Competitive Scenario:

Prominent players in the global alogliptin market include Takeda Pharmaceutical Company Limited, Hetero Drugs Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. Companies are focusing on strategic collaborations, launch of generic formulations, and regional expansion to consolidate their market position.

Scope of Work – Global Alogliptin Market

Key Market Developments:

2023: Takeda expanded its distribution partnerships in Latin America to increase accessibility to branded alogliptin formulations.

2024: Hetero Drugs launched a cost-effective alogliptin-metformin FDC for the Indian market.

2025: Mylan filed for regulatory approval of its alogliptin generic version in key EU countries following patent expirations.

FAQs:

1) What is the current market size of the Global Alogliptin Market?

The Global Alogliptin Market was valued at USD 675 million in 2023.

2) What is the major growth driver of the Global Alogliptin Market?

The primary growth driver is the rising prevalence of type 2 diabetes and increasing demand for effective oral antidiabetic therapies.

3) Which is the largest region during the forecast period in the Global Alogliptin Market?

North America is expected to remain the leading region due to high adoption and strong healthcare infrastructure.

4) Which segment accounted for the largest market share in Global Alogliptin Market?

The oral tablet formulation segment held the largest market share in 2023.

5) Who are the key market players in the Global Alogliptin Market?

Key players include Takeda Pharmaceutical, Hetero Drugs, Mylan N.V., Sun Pharma, and Teva Pharmaceutical.